Insider buying last 90 days
No open-market insider purchases were filed for TFX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Teleflex moved higher this week after third-quarter results showed a raised 2026 adjusted earnings outlook and a return to growth in the Interventional business, though the company noted a planned divestiture could close later than expected. Third-quarter revenue came in essentially flat year over year at $567.78 million, while net income turned positive to $927.43 million on a $1.0 billion pretax gain from the OEM business sale, pushing diluted EPS to $22.28. Adjusted EPS rose 39.2% year over year to $2.63 on 3% pro forma adjusted constant currency revenue growth and a 25% adjusted operating margin, beating consensus, though at least one report flagged scrutiny over guidance quality given the recent rally. The company also declared a quarterly dividend of $0.34 per share, payable 31 December to shareholders of record 16 November.
The stock closed at $154.73, up 2.6%, sitting above both its 50-day ($132.43) and 200-day ($126.50) moving averages, with the 50-day above the 200-day, and trading near its 52-week high of $156.67. The GekkoIndex reads 34.9, placing it in the Distribution zone, down 8.2 over the past five readings. Price sits 18.8% above Gekko Fair Value of $130.21.
The next earnings date falls on 25 February 2027, 107 days out, beyond a typical 20-trading-day hold. No insider, Congress or unusual options activity appears in their respective windows, though one billionaire holder is recorded. Seasonality over the next 20 trading days has averaged +4.2% across 5 years, rising in 3 of them. Analyst coverage from 10 firms shows 6 buy and 4 hold ratings, with a consensus target of $154, implying consensus downside of -0.5% from current levels.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Teleflex scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed2 headwinds
Above 50 and 200-day
Close $155.10 is above the 50-day ($133.56) and 200-day ($127.51) averages, and the 50-day is above the 200-day.
See the chart43.6, Distribution
Reading 43.6 is in the Distribution zone.
See the GekkoIndex19.7% above
Price is 19.7% above Gekko Fair Value (more than 5% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 102 days
Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.
See earnings+8.6% on average
From this point in the calendar, the next 20 trading days averaged +8.6% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Teleflex closed at $155.10 on Nov 13, 2026, +39.1% over the past year, inside a 52-week range of $100.18 to $156.75.
Use the left and right arrow keys to read daily values.
Put TFX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Teleflex designs and produces disposable medical devices that clinicians rely on for both diagnosis and treatment, mainly in surgical and critical care settings. It has built recognition around its Arrow-branded vascular access tools, such as catheters and systems for guiding and positioning catheter tips, as well as the UroLift System, which addresses urinary symptoms tied to enlarged prostate conditions.
The business spans multiple product areas, including vascular access, interventional cardiology and radiology, anesthesia and surgical equipment, urology, and respiratory care. Offerings under these areas include coronary and structural heart devices, tools for peripheral vascular and cardiac procedures, pain management and surgical instruments, catheterization and endourology equipment, plus devices for oxygen delivery and breathing support. Buyers of these products include hospitals, clinicians, emergency responders, military medical units, other device makers, and providers of home healthcare.
Teleflex traces its founding to 1943 and runs its operations from Wayne, Pennsylvania. Its stock trades on the NYSE under the symbol TFX.
Teleflex’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 43.6, in the Distribution zone, up 8.5 points over five sessions.
Up 8.5 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 55 | −0.2% | +1.0% | ||
| Accumulation | 291 | +0.4% | −0.4% | ||
| Neutral | 338 | −0.7% | −2.4% | ||
| Distribution (current zone) | 16 | −1.8% | −5.0% | ||
| Selling | 2 | Too few readings yet | |||
Average TFX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
Teleflex trades 19.7% above Gekko Fair Value of $129.57, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Teleflex shares are worth, recalculated every trading day.
$129.57
Gekko Fair Value, Nov 14, 2026
19.7% Overvalued
At the end of Aug 2026 the price was 4.4% above the estimate.
No open-market insider purchases were filed for Teleflex, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for TFX in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in TFX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Teleflex has been buying back its own shares.
From company filings.
0of the funds Gekko tracks hold TFX.
Teleflex reports on Feb 25, 2027, before the open (102 days away), and beat the EPS estimate in 7 of its last 8 reports.
Feb 25, 2027
Expected before the open, 102 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $1.76 est $1.28 | $570.3M est $559.6M | −1.3% |
| May 7, 2026 | $1.39 est $1.21 | $548.3M est $536.9M | +8.0% |
| Feb 26, 2026 | $1.93 est $3.73 | $569.0M est $919.3M | +9.1% |
| Nov 6, 2025 | $3.67 est $3.38 | $913.0M est $915.0M | −12.3% |
| Jul 31, 2025 | $3.73 est $3.36 | $780.9M est $892.9M | +1.7% |
| May 1, 2025 | $2.91 est $2.88 | $700.7M est $766.1M | −7.8% |
| Feb 27, 2025 | $3.89 est $3.86 | $795.4M est $767.1M | −25.3% |
| Oct 31, 2024 | $3.49 est $3.39 | $764.4M est $813.3M | −10.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Teleflex is $168.09, +8.4% from the last close, from 9 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 9 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 9 | Truist Financial | $167 | +7.7% |
| Nov 6 | Bank of America Securities | — | — |
| Nov 6 | Raymond James | $165 | +6.4% |
| Nov 6 | BMO Capital | $169 | +9.0% |
| Nov 6 | Wells Fargo | $167 | +7.7% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Teleflex averaged +8.6% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | 0.0% | 3 of 5 |
| Next 10 trading days | +1.4% | 3 of 5 |
| Next 15 trading days | +5.0% | 3 of 5 |
| Next 20 trading days | +8.6% | 3 of 5 |
| Next 30 trading days | +8.4% | 3 of 5 |
For scale, TFX’s typical 20-trading-day move in either direction is about 5.9%.
Teleflex’s market cap is $6.15B, with a P/E ratio of 75.4 and revenue of $2.26B over the last twelve months.
Coverage of Teleflex this week reads positive: 6 positive, 2 neutral and 0 negative headlines.
Teleflex’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 15.0% above |
| ABTAbbott Laboratories | Neutral | 10.5% below |
| DHRDanaher | Neutral | 4.7% above |
| ISRGIntuitive Surgical | Neutral | 17.5% above |
| MDTMedtronic | Neutral | 14.2% below |
| SYKStryker | Neutral | 0.1% below |
A peer links to its own page where one exists.
Teleflex’s market cap is $6.15B at the Nov 13, 2026 close of $155.10, with 39.66M shares outstanding. The shares trade on a P/E ratio of 75.4.
The consensus analyst 12-month price target for Teleflex is $168.09, +8.4% from the last close. Of the 9 firms that rated the stock in the last 90 days, 6 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Teleflex is overvalued: the Nov 13, 2026 close of $155.10 is 19.7% above Gekko Fair Value of $129.57. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Teleflex is expected to report on Feb 25, 2027, before the market opens (102 days away). Analysts expect earnings of $1.92 per share on revenue of $577.9M. Teleflex beat the earnings estimate in 7 of its last 8 reports, moving 9.5% on average across the report.
Teleflex’s 52-week high is $156.75 and its 52-week low is $100.18; it closed at $155.10 on Nov 13, 2026, +39.1% over the past year. Over the last five years the shares peaked at $356.72 on Apr 4, 2022.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality) and 2 as headwinds (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.